Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

Amy D Shapiro, K John Pasi, Margareth C Ozelo, Roshni Kulkarni, Christopher Barnowski, Bent Winding, Johan Szamosi, Stefan Lethagen, Amy D Shapiro, K John Pasi, Margareth C Ozelo, Roshni Kulkarni, Christopher Barnowski, Bent Winding, Johan Szamosi, Stefan Lethagen

Abstract

Background: In the phase 3 B-LONG study (NCT01027364), prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) every 7 to >14 days was associated with low annualized bleed rates (ABRs) in males aged ≥12 years with severe hemophilia B. The long-term safety and efficacy of rFIXFc prophylaxis was confirmed in the B-YOND study (NCT01425723), an extension of the B-LONG clinical trial.

Objective: The aim of this post-hoc analysis was to evaluate the efficacy of a ≥14-day rFIXFc dosing interval in patients treated prophylactically during B-LONG or B-YOND.

Methods: The analysis included 22 patients aged ≥12 years who received prophylactic rFIXFc with a ≥14-day dosing interval at any time during B-LONG or B-YOND up until the second interim analysis of B-YOND (September 2015).

Results: The median (interquartile range [IQR]) rFIXFc exposure on the ≥14-day dosing interval was 3.4 (1.8-4) years. Patients treated with a ≥14-day dosing interval were well controlled with a median (IQR) overall ABR of 1.6 (0.6-2.7) and a median (IQR) spontaneous ABR of 0.7 (0.3-1.1) in 18 evaluable patients. A rFIXFc dosing interval of ≥14 days was well tolerated, with no new safety concerns identified.

Conclusion: Most patients on rFIXFc prophylaxis, with a dosing interval of ≥14 days, remained well controlled; ABRs were consistent with those reported in the overall study population. A ≥14-day dosing interval can be utilized in some well controlled individuals and reduces the burden imposed by frequent prophylactic injections while maintaining adequate bleed suppression.

Keywords: clinical trial; factor IX; hemophilia B; prophylaxis; recombinant fusion proteins.

Figures

Figure 1
Figure 1
Study flow in B‐LONG and the B‐YOND extension study

References

    1. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe hemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329–35.
    1. Manco‐Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–44.
    1. Hacker MR, Geraghty S, Manco‐Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7:392–6.
    1. McCue J, Osborne D, Dumont J, et al. Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein. Haemophilia. 2014;20:e327–35.
    1. Swedish Orphan Biovitrum Ltd 2017. ALPROLIX powder and solvent for solution for injection: summary of product characteristics. [Accesssed 2018 November 9] Available from: _GB/document_library/EPAR_Product_Information/human/004142/WC500207015.pdf.
    1. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–23.
    1. Pasi KJ, Fischer K, Ragni M, et al. Long‐term safety and efficacy of extended‐interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017;117:508–18.
    1. Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B‐LONG): results from a multicentre, non‐randomised phase 3 study. Lancet Haematol. 2017;4:e75–82.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever